Product Description
Inhibitor of RORC (Sourced from: https://www.chemicalprobes.org/vimirogant)
Mechanisms of Action: RORG Antagonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: AbbVie
Company Location: NORTH CHICAGO IL 60064
Company CEO: Richard A. Gonzalez
Additonal Commercial Interests: None
Clinical Description
![Map of Global Clinical Trials for Vimirogant](https://pryzm-maps.s3.us-west-2.amazonaws.com/666666current_maps.png)
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Psoriasis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
VTP-43742-002-1 | P1 |
Completed |
Psoriasis |
2016-03-08 |
22% |
VTP-43742-002 | P2 |
Completed |
Psoriasis |
2016-03-01 |
39% |